摘要
目的探讨消银颗粒联合他克莫司对慢性湿疹患者T淋巴细胞和可溶性白细胞介素-2受体(SIL-2R)的影响。方法选取我院2018年2月—2019年2月收治的116例慢性湿疹患者作为研究对象,采用电脑随机分组的方式分为对照组以及研究组,每组各58例。对照组给予他克莫司治疗,研究组给予消银颗粒联合他克莫司治疗。分析对比2组患者疗效。结果研究组治疗有效率显著高于对照组(91.38%比74.14%,P<0.05),研究组湿疹面积和严重程度指数(EASI)评分、瘙痒程度视觉模拟评分(VAS)显著低于对照组(P<0.05)。研究组CD4^(+)T、CD4^(+)T/CD8^(+)T显著高于对照组,CD8^(+)T显著低于对照组(P<0.05)。研究组血清SIL-2R水平显著低于对照组(pg/mL:225.18±46.85比338.75±45.67,P<0.05)。研究组与对照组不良反应发生率比较差异无统计学意义(3.45%比6.90%,P>0.05)。结论消银颗粒联合他克莫司可有效的改善慢性湿疹患者患者的T淋巴细胞水平,降低SIL-2R水平,改善临床症状,值得推广。
Objective In order to explore the effect of Xiaoyin granule combined with tacrolimus on T lymphocytes and soluble interleukin-2 receptor(SIL-2R)in patients with chronic eczema.Methods Totally 116 cases of chronic eczema treated in our hospital from February 2018 to February 2019 were selected as research objects.They were randomly divided into control group and study group,with 58 cases in each group.The control group was treated with tacrolimus,while the study group was treated with Xiaoyin granule combined with tacrolimus.The curative effects of both groups were analyzed and compared.Results The effective rate of the study group was 91.38%,which was significantly higher than that of the control group(74.14%,P<0.05).The area and severity index(EASI)score of eczema and visual analogue scale(VAS)of itching in the study group were significantly lower than those in the control group(P<0.05).The CD4^(+)T and CD4^(+)T/CD8^(+)T in the study group were significantly higher than those in the control group,while CD8^(+)T was lower than that in the control group(P<0.05).Serum SIL-2R level in study group was significantly lower than that in control group(pg/mL:225.18±46.85 vs.338.75±45.67,P<0.05).There was no statistically significant difference in the adverse reaction rate of study group and control group was(3.45%vs.6.90%,P>0.05).Conclusion Xiaoyin granule combined with tacrolimus can effectively improve T lymphocyte level,reduce SIL-2R level and improve clinical symptoms in patients with chronic eczema,which is worth popularizing.
作者
赵玲玲
梅红
许阳
Zhao Lingling;Mei Hong;Xu Yang(Rugao Hospital Affiliated to Nantong University,Rugao 226500,Jiangsu,China;The Second Hospital of the First Affiliated Hospital of Nanjing Medical University,Nanjing 210000,Jiangsu,China)
出处
《中国中西医结合皮肤性病学杂志》
CAS
2023年第3期246-250,共5页
Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine
基金
国家自然科学基金(编号:81301384)。